凝固因子欠乏症の世界市場レポート 2025年

凝固因子欠乏症市場規模は、今後数年間で力強い成長が見込まれます。2029年には複合年間成長率（CAGR）7.7％で66億4,000万米ドルに成長します。予測期間中の成長は、遺伝子治療の採用拡大、個別化医療への注目の高まり、凝固障害の有病率の上昇、新興市場における治療アクセスの拡大、バイオ製造技術の継続的な進歩に伴うデジタルヘルスソリューションの統合によってもたらされます。主な動向としては、CRISPRなどの遺伝子編集技術の出現、長時間作用型組換え因子の開発、遺伝子治療デリバリーシステムの革新、ウェアラブル凝固モニタリングデバイス、AIによる治療最適化、ポイントオブケア診断ツールの進歩、ナノ粒子ベースのドラッグデリバリー、無血漿組換え製剤の開発、バイオシミラー革新、精密医療アプローチの統合などが挙げられます。

血液関連疾患の増加は、凝固因子欠乏症市場の成長を促進すると予想されます。血液関連疾患には、血液細胞、血小板、血漿の産生、機能、組成に影響を与え、貧血、凝固障害、免疫不全などの合併症を引き起こす疾患が含まれます。これらの疾患の増加は、人口の高齢化、遺伝的素因、意識の高まり、環境の影響、ライフスタイルの変化、慢性疾患の負担増、早期発見を可能にする診断技術の進歩などの要因によるものです。凝固因子欠乏症は、血栓を形成する身体の自然な能力が損なわれている血友病などの状態において、過剰な出血を予防または抑制するために必要な必須凝固因子を供給することにより、血液関連疾患の管理において重要な役割を果たしています。例えば、2024年9月、米国を拠点とする専門組織である白血病リンパ腫協会は、米国では3分に1人が白血病、リンパ腫、骨髄腫と診断されていると報告しました。2024年には、推定18万7,740人がこれらのがんと診断され、米国で予測される新規がん患者数200万1,140人の9.4％を占める。さらに2024年5月、英国の政府系ヘルスケアシステムであるNHSイングランドは、英国では遺伝性血液疾患である鎌状赤血球症を持つ人が約1万7,000人おり、毎年約250人が新たに鎌状赤血球症と診断されていることを明らかにしました。その結果、血液関連疾患の有病率の増加が凝固因子欠乏症市場の成長に拍車をかけています。

凝固因子欠乏症市場の主要企業は、血友病のような出血性疾患の患者に長期的または治癒の可能性のある解決策を提供し、それによって生涯にわたる凝固因子の注入の必要性を減らすために、1回限りの遺伝子治療のような画期的な治療法の開発に注力しています。一回限りの遺伝子治療は、患者の細胞内に遺伝物質を導入または改変して病気を治療または治癒するもので、1回の治療で持続的または永続的な治療効果を得ることを目的としています。例えば、2024年4月、米国の製薬・バイオテクノロジー企業であるファイザー社は、現在第IX因子（FIX）予防療法に頼っている中等症から重症の成人血友病Bの治療薬として、BEQVEZ（fidanacogene elaparvovec-dzkt）を米国食品医薬品局（FDA）が承認したと発表しました。この1回限りのアデノ随伴ウイルス（AAV）ベースの遺伝子治療は、高活性FIX変種をコードするFIX遺伝子の機能的コピーを形質導入細胞に導入するように設計されています。血友病B患者にとって、この治療法はFIXを独立して産生することを可能にし、頻繁なFIX点滴の必要性をなくします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界凝固因子欠乏症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の凝固因子欠乏症市場：成長率分析
• 世界の凝固因子欠乏症市場の実績：規模と成長, 2019-2024
• 世界の凝固因子欠乏症市場の予測：規模と成長, 2024-2029, 2034F
• 世界凝固因子欠乏症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の凝固因子欠乏症市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組換え凝固因子濃縮物
• 血漿由来凝固因子濃縮物
• 生物学的製剤
• デスモプレシン
• その他の製品タイプ
• 世界の凝固因子欠乏症市場欠乏症の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血友病A
• 血友病B
• フォン・ヴィレブランド病
• 第XI因子欠乏症
• 第XIII因子欠乏症
• その他の治療の種類
• 世界の凝固因子欠乏症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• ホームケア
• 他のEnsユーザー
• 世界の凝固因子欠乏症市場組換え凝固因子濃縮物の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組換え因子VIII
• 組換え因子IX
• 組換え因子VIIa
• その他の組み換え因子
• 世界の凝固因子欠乏症市場血漿由来凝固因子濃縮物の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血漿由来第VIII因子
• 血漿由来第IX因子
• 血漿由来第VII因子
• その他の血漿由来因子
• 世界の凝固因子欠乏症市場、生物製剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 遺伝子治療製品
• 世界の凝固因子欠乏症市場デスモプレシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内デスモプレシン
• 鼻腔内デスモプレシン
• 世界の凝固因子欠乏症市場、その他の製品タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 新鮮凍結血漿（FFP）
• プロトロンビン複合体濃縮物（PCC）

第7章 地域別・国別分析

• 世界の凝固因子欠乏症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の凝固因子欠乏症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 凝固因子欠乏症市場：競合情勢
• 凝固因子欠乏症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer HealthCare Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Genzyme Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Baxter International Inc.
• CSL Behring LLC
• Grifols S.A.
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Swedish Orphan Biovitrum AB
• GC Biopharma Co. Ltd.
• Alnylam Pharmaceuticals Inc.
• Opko Health Inc.
• Kedrion Biopharma Inc.
• Shanghai RAAS Blood Products Co. Ltd.
• LFB S.A.
• Biotest AG
• Spark Therapeutics Inc.
• Biogen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 凝固因子欠乏症市場2029：新たな機会を提供する国
• 凝固因子欠乏症市場2029：新たな機会を提供するセグメント
• 凝固因子欠乏症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Coagulation factor deficiency is a condition in which the body lacks one or more essential clotting factors required for proper blood coagulation, resulting in prolonged bleeding or difficulty in stopping bleeding. Treatment involves the use of clotting factor concentrates and other therapies to manage and prevent bleeding episodes in individuals with conditions such as hemophilia.

The primary product types for treating coagulation factor deficiency include recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, biologics, desmopressin, and others. Recombinant coagulation factor concentrates are lab-engineered proteins designed to replace missing clotting factors in affected patients. The deficiency types include hemophilia A, hemophilia B, von Willebrand disease, factor XI deficiency, factor XIII deficiency, and others. These treatments are utilized across various healthcare settings, including hospitals, clinics, home care, and more.

The coagulation factor deficiency market research report is one of a series of new reports from The Business Research Company that provides coagulation factor deficiency market statistics, including coagulation factor deficiency industry global market size, regional shares, competitors with a coagulation factor deficiency market share, detailed coagulation factor deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the coagulation factor deficiency industry. This coagulation factor deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coagulation factor deficiency market size has grown strongly in recent years. It will grow from $4.58 billion in 2024 to $4.94 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth during the historic period was driven by the rising prevalence of hemophilia, the introduction of recombinant clotting factors, increased awareness of coagulation disorders, advancements in diagnostic capabilities, government support for rare diseases, the development of prophylactic therapies, the expansion of patient registries, and growing investments in biotechnology.

The coagulation factor deficiency market size is expected to see strong growth in the next few years. It will grow to $6.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The projected growth during the forecast period is driven by the increasing adoption of gene therapies, a stronger focus on personalized medicine, the rising prevalence of coagulation disorders, expanding treatment access in emerging markets, and the integration of digital health solutions alongside continuous advancements in biomanufacturing technologies. Key trends include the emergence of gene editing technologies such as CRISPR, the development of long-acting recombinant factors, innovations in gene therapy delivery systems, wearable coagulation monitoring devices, AI-driven treatment optimization, advancements in point-of-care diagnostic tools, nanoparticle-based drug delivery, plasma-free recombinant product development, biosimilar innovation, and the integration of precision medicine approaches.

The rising incidences of blood-related disorders are expected to drive the growth of the coagulation factor deficiency market. Blood-related disorders encompass conditions that affect the production, function, or composition of blood cells, platelets, or plasma, leading to complications such as anemia, clotting issues, or immune system deficiencies. The increase in these disorders is attributed to factors such as aging populations, genetic predispositions, rising awareness, environmental influences, lifestyle changes, the growing burden of chronic diseases, and advancements in diagnostic technologies that enable earlier detection. Coagulation factor deficiency plays a vital role in managing blood-related disorders by supplying essential clotting factors needed to prevent or control excessive bleeding in conditions such as hemophilia, where the body's natural ability to form blood clots is impaired. For example, in September 2024, the Leukemia and Lymphoma Society, a US-based professional organization, reported that every three minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma. In 2024, an estimated 187,740 individuals were diagnosed with these cancers, accounting for 9.4% of the projected 2,001,140 new cancer cases in the US. Additionally, in May 2024, NHS England, a UK-based government-funded healthcare system, revealed that approximately 17,000 people in England are living with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed annually. As a result, the increasing prevalence of blood-related disorders is fueling the growth of the coagulation factor deficiency market.

Leading companies in the coagulation factor deficiency market are focusing on developing groundbreaking therapies, such as one-time gene therapy, to offer long-term or potentially curative solutions for patients with bleeding disorders such as hemophilia, thereby reducing the need for lifelong infusions of clotting factors. One-time gene therapy involves introducing or modifying genetic material within a patient's cells to treat or cure a disease, with the goal of providing sustained or permanent therapeutic effects after a single treatment. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved BEQVEZ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently rely on factor IX (FIX) prophylaxis therapy. This one-time adeno-associated virus (AAV)-based gene therapy is designed to introduce a functional copy of the FIX gene encoding a high-activity FIX variant into transduced cells. For patients with hemophilia B, this therapy enables them to produce FIX independently, eliminating the need for frequent FIX infusions.

In March 2024, ReciBioPharm, a US-based contract development and manufacturing organization (CDMO) in the pharmaceutical industry, partnered with GeneVentiv Therapeutics to advance the development of an adeno-associated virus (AAV)-based universal gene therapy for hemophilia, marking the first treatment for hemophilia patients with inhibitors. Through this collaboration, ReciBioPharm will expedite the development of the technology using its state-of-the-art AAV manufacturing platform. GeneVentiv Therapeutics, a US-based preclinical gene therapy company, is working to pioneer innovative treatments that could revolutionize hemophilia management.

Major players in the coagulation factor deficiency market are Pfizer Inc., F Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, GC Biopharma Co. Ltd., Alnylam Pharmaceuticals Inc., Opko Health Inc., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, Spark Therapeutics Inc., Biogen Inc., Sangamo Therapeutics Inc., Centessa Pharmaceuticals Inc.

North America was the largest region in the coagulation factor deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in coagulation factor deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the coagulation factor deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The coagulation factor deficiency market consists of sales of factor VIII concentrates, prothrombin complex concentrates, and fresh frozen plasma (FFP). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Coagulation Factor Deficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on coagulation factor deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for coagulation factor deficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The coagulation factor deficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Recombinant Coagulation Factor Concentrates; Plasma-derived Coagulation Factor Concentrates; Biologics; Desmopressin; Other Product Types
• 2) By Deficiency Type: Haemophilia A; Hemophilia B; Von Willebrand Disease; Factor XI Deficiency; Factor XIII Deficiency; Other Treatment Types
• 3) By End Users: Hospitals; Clinics; Home Care; Other End Users
• Subsegments:
• 1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII; Recombinant Factor IX; Recombinant Factor VIIa; Other Recombinant Factors
• 2) By Plasma-derived Coagulation Factor Concentrates: Plasma-derived Factor VIII; Plasma-derived Factor IX; Plasma-derived Factor VII; Other Plasma-derived Factors
• 3) By Biologics: Monoclonal Antibodies; Gene Therapy Products
• 4) By Desmopressin: Intravenous Desmopressin; Intranasal Desmopressin
• 5) By Other Product Types: Fresh Frozen Plasma (FFP); Prothrombin Complex Concentrates (PCC)
• Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd.; Bayer HealthCare Pharmaceuticals; Sanofi Genzyme; Novo Nordisk A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Coagulation Factor Deficiency Market Characteristics

3. Coagulation Factor Deficiency Market Trends And Strategies

4. Coagulation Factor Deficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Coagulation Factor Deficiency Growth Analysis And Strategic Analysis Framework

• 5.1. Global Coagulation Factor Deficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Coagulation Factor Deficiency Market Growth Rate Analysis
• 5.4. Global Coagulation Factor Deficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Coagulation Factor Deficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Coagulation Factor Deficiency Total Addressable Market (TAM)

6. Coagulation Factor Deficiency Market Segmentation

• 6.1. Global Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Coagulation Factor Concentrates
• Plasma-derived Coagulation Factor Concentrates
• Biologics
• Desmopressin
• Other Product Types
• 6.2. Global Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Haemophilia A
• Hemophilia B
• Von Willebrand Disease
• Factor XI Deficiency
• Factor XIII Deficiency
• Other Treatment Types
• 6.3. Global Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care
• Other Ens Users
• 6.4. Global Coagulation Factor Deficiency Market, Sub-Segmentation Of Recombinant Coagulation Factor Concentrates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Factor VIII
• Recombinant Factor IX
• Recombinant Factor VIIa
• Other Recombinant Factors
• 6.5. Global Coagulation Factor Deficiency Market, Sub-Segmentation Of Plasma-derived Coagulation Factor Concentrates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasma-derived Factor VIII
• Plasma-derived Factor IX
• Plasma-derived Factor VII
• Other Plasma-derived Factors
• 6.6. Global Coagulation Factor Deficiency Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Gene Therapy Products
• 6.7. Global Coagulation Factor Deficiency Market, Sub-Segmentation Of Desmopressin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Desmopressin
• Intranasal Desmopressin
• 6.8. Global Coagulation Factor Deficiency Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fresh Frozen Plasma (FFP)
• Prothrombin Complex Concentrates (PCC)

7. Coagulation Factor Deficiency Market Regional And Country Analysis

• 7.1. Global Coagulation Factor Deficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Coagulation Factor Deficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Coagulation Factor Deficiency Market

• 8.1. Asia-Pacific Coagulation Factor Deficiency Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Coagulation Factor Deficiency Market

• 9.1. China Coagulation Factor Deficiency Market Overview
• 9.2. China Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Coagulation Factor Deficiency Market

• 10.1. India Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Coagulation Factor Deficiency Market

• 11.1. Japan Coagulation Factor Deficiency Market Overview
• 11.2. Japan Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Coagulation Factor Deficiency Market

• 12.1. Australia Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Coagulation Factor Deficiency Market

• 13.1. Indonesia Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Coagulation Factor Deficiency Market

• 14.1. South Korea Coagulation Factor Deficiency Market Overview
• 14.2. South Korea Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Coagulation Factor Deficiency Market

• 15.1. Western Europe Coagulation Factor Deficiency Market Overview
• 15.2. Western Europe Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Coagulation Factor Deficiency Market

• 16.1. UK Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Coagulation Factor Deficiency Market

• 17.1. Germany Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Coagulation Factor Deficiency Market

• 18.1. France Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Coagulation Factor Deficiency Market

• 19.1. Italy Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Coagulation Factor Deficiency Market

• 20.1. Spain Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Coagulation Factor Deficiency Market

• 21.1. Eastern Europe Coagulation Factor Deficiency Market Overview
• 21.2. Eastern Europe Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Coagulation Factor Deficiency Market

• 22.1. Russia Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Coagulation Factor Deficiency Market

• 23.1. North America Coagulation Factor Deficiency Market Overview
• 23.2. North America Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Coagulation Factor Deficiency Market

• 24.1. USA Coagulation Factor Deficiency Market Overview
• 24.2. USA Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Coagulation Factor Deficiency Market

• 25.1. Canada Coagulation Factor Deficiency Market Overview
• 25.2. Canada Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Coagulation Factor Deficiency Market

• 26.1. South America Coagulation Factor Deficiency Market Overview
• 26.2. South America Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Coagulation Factor Deficiency Market

• 27.1. Brazil Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Coagulation Factor Deficiency Market

• 28.1. Middle East Coagulation Factor Deficiency Market Overview
• 28.2. Middle East Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Coagulation Factor Deficiency Market

• 29.1. Africa Coagulation Factor Deficiency Market Overview
• 29.2. Africa Coagulation Factor Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Coagulation Factor Deficiency Market, Segmentation By Deficiency Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Coagulation Factor Deficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Coagulation Factor Deficiency Market Competitive Landscape And Company Profiles

• 30.1. Coagulation Factor Deficiency Market Competitive Landscape
• 30.2. Coagulation Factor Deficiency Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer HealthCare Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi Genzyme Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

31. Coagulation Factor Deficiency Market Other Major And Innovative Companies

• 31.1. Baxter International Inc.
• 31.2. CSL Behring LLC
• 31.3. Grifols S.A.
• 31.4. Octapharma AG
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Swedish Orphan Biovitrum AB
• 31.7. GC Biopharma Co. Ltd.
• 31.8. Alnylam Pharmaceuticals Inc.
• 31.9. Opko Health Inc.
• 31.10. Kedrion Biopharma Inc.
• 31.11. Shanghai RAAS Blood Products Co. Ltd.
• 31.12. LFB S.A.
• 31.13. Biotest AG
• 31.14. Spark Therapeutics Inc.
• 31.15. Biogen Inc.

32. Global Coagulation Factor Deficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Coagulation Factor Deficiency Market

34. Recent Developments In The Coagulation Factor Deficiency Market

35. Coagulation Factor Deficiency Market High Potential Countries, Segments and Strategies

• 35.1 Coagulation Factor Deficiency Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Coagulation Factor Deficiency Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Coagulation Factor Deficiency Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer